Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

MedWorld Advisors United States

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.
Website:
www.medworldadvisors.com
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Looking for
Please specify your partnering goal
We currently have 10 Medical Technology projects that may be interesting for the China market. We seek to meet appropriate China partners for these projects.
Headquartner in China
No
Plan in China
We have projects in medical imaging, image processing, endoscopy, endo-vascular, hemodynamics, oximetry, digital health, wearables, and wound care that may be interesting for the China market.
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
Multiple Projects|Open for Licensing / Acquisition|FDA Cleared|US, EU and Israel
Medtech Development Stage
Dave Sheppard
Managing Director 
Functionality
Business Development

Mission Bio United States

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.

Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.
Website:
www.missionbio.com
Year of foundation
2014
Looking for
Please specify your partnering goal
We are hoping to identify key commercial opportunities in academic, government, and industry centers. We have local representatives that assist with relationship management, procurement, services, etc.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
Tapestri Platform|The Tapestri Platform is the only system capable of simultaneously providing both genotype and phenotype data from the same cell, across thousands of single cells. With DNA as a foundation, our proprietary two-step microfluidic workflow enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins. Meet the complexity of cancer with true multi-omics analysis.|||
Biotech/Pharma Asset Stage
Zachary Fernandes
Associate Director, Global Channel Development 
Functionality
Business Development

Mybiogate Inc. United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Lili Jiang
Business Manager 
Suzanne Ferguson
Operation Manager 
Miao Guo
VP, Marketing and Operations 
Xiaojia Zhang
Director 
Wenjie Xu
Investment Manager 
Feier Chen
Marketing Manager 
Dan Lei
CEO 
Wei Ji
VP 
Xinxin Li
VP, Strategic Partnership 
Youwen Dai
BD Director 
Syliva Siu
Lucky Chen
Kun Tao
Functionality
Investment

Nenupharma Life Science Consulting United States

Nenupharma was born out of a shared passion to contribute to the development of innovative pharmaceuticals in different disease areas.

Nenupharma uses the best of skills that have been developed through an extensive career in pharmaceutical industry, regulatory affairs, market access, medical practice and life science.

Nenupharma has been working with high level experts on different levels and enjoys reliable, professional and ethical reputation among its network as well as its customers.

For more information, visit our website at:
www.nenupharma.com
Website:
www.nenupharma.com
Looking for
Headquartner in China
No
Karim BA
CEO 
Functionality
Business Development

Nova Clinical Solutions, Inc. United States

华诺临床立足于海外,为全球客户提供医药产品在北美进行 FDA 临床报批、临床试验运营、临床数据分析与管理等一系列服务。专业的团队,丰富的经验以及客户至上的合作理念会助您拓展在海外的临床开发业务。客户的满意与成功是我们追求的终极目标。
Website:
https://www.huanuoclinical.com/
Looking for
Headquartner in China
No
Service Description
研发工具或服务 Research tools and services: Clinical CRO, Regulatory Consulting
Jacky Wang
President 

OniX Hub United States

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)
Website:
https://www.onixhub.com/ | https://www.onixempirefund.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Funded
Headquartner in China
No
Plan in China
TBD
Martin Duenas
Founder/CEO 
Functionality
Management

OROX BioSciences United States

OROX BioSciences is an early-stage biotech startup involved in discovery/development of small molecules capable of treating fibrosis, inflammation, and oncology.
Website:
www.oroxbios.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Funding Status
Self and seed funding
Headquartner in China
No
Plan in China
Development of relationship with Chinese investors and biopharmaceutical industry. Also, we hope to be able to develop our small molecule therapeutics in China with the aid of a Chinese development partner.
Mehran Moghaddam
CEO 
Functionality
Management

PhysioCue United States

PhysioCue is digital health and therapy device development company, located in the heart of Silicon Valley, California. PhysioCue has developed the thermal neurostimulation technology for a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile app. Using our device once daily for 5-minute treatments gradually elongated the reduced blood pressure. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with drugs. We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhysioCue devices can help people and save lives.
Website:
https://physiocue.com
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Looking for
Funding Status
PhysioCue is seeking to raise $7M for a syndicate in our Series A round of financing.
Headquartner in China
No
Plan in China
Set up a JV in China and looking for a distribution partner.
Medtech Category
Simon Yi
LinkedIn logo President 
Functionality
Management

Ping Rawson United States

Dyadic International, Inc. is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, based on a patented and proprietary genetically modified strain of the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), to address opportunities in the human and animal health markets. C1 is a potentially game-changing biopharmaceutical gene expression platform that may help bring biologic vaccines, drugs and other biologic products to market faster and more efficiently than existing expression platforms, such as Chinese hamster ovary (CHO) cells, E. coli, yeast and baculovirus in greater volumes, at lower cost and with new properties that can improve access and cost to patients and the healthcare system.

Website:
http://www.dyadic.com
Year of foundation
1979
Looking for
Headquartner in China
No
Plan in China
Looking for business partners and collaborations in China.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Ping Rawson CFO 
Functionality
Management

Pleiogenix Inc. United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial diseases that Pleiogenix is targeting are acute alcoholic hepatitis (AAH), COVID-19, and non-alcoholic steatohepatitis (NASH) / Fibrosis, with additional diseases to follow. AAH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. NASH is a severe form of the chronic liver disease, non-alcoholic fatty liver disease (NAFLD). The AAH market is estimated to be $575 million by 2023, while the NASH market is estimated to be $35-40 billion by 2025. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; there have been ~34 million cases resulting in over 1,000,000 deaths (globally). There are no approved therapeutics that prevent or treat AAH, NASH, or COVID-19. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic and metabolic clinical benefits. In patients suffering from AAH, NASH, and COVID-19, inflammation is severely increased, and adiponectin is reduced in patients with NASH. Increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical for AAH, NASH / fibrosis, and/or COVID-19.
Website:
www.pleiogenix.com (under construction)
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Currently seeking $1 million Seed funding; detailed Use of Funds / Budget available
Headquartner in China
No
Plan in China
Plan to Enter China Market 1. PLG888 will be out-licensed to a commercialization partner to serve the China Market 2. China Market can be served by a specific licensing agreement, or as part of a broader licensing Asia-targeted agreement, that includes Japan, Korea, etc; this is open for discussion. 3. Overall Out-Licensing Strategy: restricted to specific indication and by specific world area (eg North America, EU, UK, Asia); some commercialization partners might prefer worldwide commercialization rights 4. Timing: AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration; NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) 5. Revenue Model for Pleiogenix: Revenues will be derived from License and Milestone payments and Royalties on sales 6. EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements within 3-5 years. AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) Revenue Model for Pleiogenix Revenues will be derived from License and Milestone payments and Royalties on sales EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements
Joseph Evans
CEO & President 
Functionality
Management